Dose to the source trial.
Each active is dosed at the level used in the trial cited as evidence of efficacy. Compounds that cannot be included at trial-level dose are excluded.
§ 01OriginFormulation history
§ 01 — Origin Filing
22 candidate compounds. Four retained.
The candidate list was assembled from a literature scan of compounds with published human-trial evidence for endogenous testosterone support in mature male subjects. The shelf at procurement time was bracketed by two failure modes: under-dosed multivitamins relabelled as "men's wellness," and synthetic anabolic compounds with documented adverse-event literature.
Specifications were drafted against the source trials. Formulator consultations were conducted in Berlin and Dublin. The candidate list was reduced from 22 compounds to 4. Each retained compound is dosed at the level used in the source trial — not the minimum effective dose, not the marketing-claim dose.
Field deployment commenced two years into the formulation programme. The unit shipping today is the third revision of the formulation. Excipients, capsule shell, and dosing have not changed since REV. 03.
